Pullman WE - Search Results

1

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE. Levy RJ, et al. Among authors: pullman we. Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9. doi: 10.1016/j.anai.2010.04.012. Ann Allergy Asthma Immunol. 2010. PMID: 20568386 Clinical Trial.

2

Ecallantide for the treatment of acute attacks in hereditary angioedema.

Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE. Cicardi M, et al. Among authors: pullman we. N Engl J Med. 2010 Aug 5;363(6):523-31. doi: 10.1056/NEJMoa0905079. N Engl J Med. 2010. PMID: 20818887 Free article. Clinical Trial.

3

Response time for ecallantide treatment of acute hereditary angioedema attacks.

Riedl M, Campion M, Horn PT, Pullman WE. Riedl M, et al. Among authors: pullman we. Ann Allergy Asthma Immunol. 2010 Dec;105(6):430-436.e2. doi: 10.1016/j.anai.2010.09.005. Epub 2010 Oct 25. Ann Allergy Asthma Immunol. 2010. PMID: 21130380

4

Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.

Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Sheffer AL, et al. Among authors: pullman we. J Allergy Clin Immunol. 2011 Jul;128(1):153-159.e4. doi: 10.1016/j.jaci.2011.03.006. Epub 2011 Apr 9. J Allergy Clin Immunol. 2011. PMID: 21481442 Clinical Trial.

5

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. MacGinnitie AJ, et al. Among authors: pullman we. Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528. Allergy Asthma Proc. 2012. PMID: 22525395

6

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE. Lumry WR, et al. Among authors: pullman we. Allergy Asthma Proc. 2013 Mar-Apr;34(2):155-61. doi: 10.2500/aap.2013.34.3653. Allergy Asthma Proc. 2013. PMID: 23484891 Clinical Trial.

7

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Sheffer AL, et al. Among authors: pullman we. Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007. Epub 2013 Jan 5. Ann Allergy Asthma Immunol. 2013. PMID: 23548529 Clinical Trial.

8

Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.

Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE. Bernstein JA, et al. Among authors: pullman we. Allergy. 2012 Sep;67(9):1173-80. doi: 10.1111/j.1398-9995.2012.02864.x. Epub 2012 Jul 5. Allergy. 2012. PMID: 22765833 Clinical Trial.

9

Economic costs associated with acute attacks and long-term management of hereditary angioedema.

Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Wilson DA, et al. Among authors: pullman we. Ann Allergy Asthma Immunol. 2010 Apr;104(4):314-20. doi: 10.1016/j.anai.2010.01.024. Ann Allergy Asthma Immunol. 2010. PMID: 20408341

10

Time to response outcomes in hereditary angioedema.

Pullman W. Pullman W. Ann Allergy Asthma Immunol. 2011 Apr;106(4):350; author reply 350-1. doi: 10.1016/j.anai.2011.01.018. Epub 2011 Mar 4. Ann Allergy Asthma Immunol. 2011. PMID: 21457889 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters